Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
|Videos|May 17, 2017
Projecting Cancer Incidence in HIV-Positive Population in the US Through 2030
Author(s)Jessica Islam, MPH
Jessica Islam, MPH, a PhD student at the University of North Carolina at Chapel Hill Gillings School of Global Public Health, discusses research that projected cancer incidence in the HIV-positive population in the United States through 2030.
Advertisement
Advertisement
Related to this article
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
2
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
3
Zabilugene Almadenorepvec Plus Chemo Shows Survival Gains in Metastatic PDAC
4
Oral Azacitidine-Cedazuridine Meets Pharmacokinetic Goal in Phase 3 MDS/CMML Trial
5